Myelodysplastic Syndromes

• 

  Subject Areas on Research

  • A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. 
  • A cord blood transplant recipient with Mycobacterium mucogenicum central venous catheter infection after infusion of tap water. 
  • A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). 
  • Acute myeloid leukemia and myelodysplastic syndromes in older adults. 
  • Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. 
  • Acute radiation injury: contingency planning for triage, supportive care, and transplantation. 
  • Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. 
  • Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. 
  • Apoptosis in haematological malignancies. 
  • Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. 
  • Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. 
  • Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. 
  • Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. 
  • Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes. 
  • Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. 
  • Colony-stimulating factors: clinical applications. 
  • Commentary: targeting myelodysplastic syndromes. 
  • Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. 
  • Congenital bone marrow failure with myelodysplasia in siblings. 
  • Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. 
  • Cyclosporin A-related cerebral vasculopathy. 
  • Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. 
  • Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. 
  • Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. 
  • Donor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: a clinicopathologic study of 10 cases and a comprehensive review of the literature. 
  • Estimation of economic costs associated with transfusion dependence in adults with MDS. 
  • Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. 
  • Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors. 
  • Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. 
  • Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. 
  • Granulocyte colony-stimulating factors and risk of acute myeloid leukemia and myelodysplastic syndrome. 
  • Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. 
  • Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. 
  • Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. 
  • Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. 
  • Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy. 
  • Lineage Switch Between B-Lymphoblastic Leukemia and Acute Myeloid Leukemia Intermediated by "Occult" Myelodysplastic Neoplasm: Two Cases of Adult Patients With Evidence of Genomic Instability and Clonal Selection by Chemotherapy. 
  • Localization of technetium-99m-sestamibi in diffuse myelodysplastic processes. 
  • Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. 
  • Long-term outcomes of myeloid growth factor treatment. 
  • MDS: unraveling the mystery. 
  • Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. 
  • Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. 
  • Myelodysplasia and deficiency of uridine diphosphate-galactose 4-epimerase. 
  • Myelodysplasia as masquerader: A woman with hypereosinophilic syndrome and twelve years of "chronic ITP". 
  • Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. 
  • Myelodysplastic syndromes clinical practice guidelines in oncology. 
  • Myelodysplastic syndromes in the United States: an update for clinicians. 
  • Myelodysplastic syndromes. 
  • Myelodysplastic syndromes: clinical practice guidelines in oncology. 
  • Myeloid Neoplasms Following Solid Organ Transplantation: Clinicopathologic Studies of 23 Cases. 
  • Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. 
  • Myeloid growth factors. 
  • Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens. 
  • NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. 
  • NCCN practice guidelines for the myelodysplastic syndromes. National Comprehensive Cancer Network. 
  • Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. 
  • Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. 
  • Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. 
  • Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. 
  • Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. 
  • Outcomes following splenectomy in patients with myeloid neoplasms. 
  • Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection. 
  • Palliative and End-of-Life Care in Myelodysplastic Syndromes. 
  • Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. 
  • Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. 
  • Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. 
  • Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. 
  • Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. 
  • Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. 
  • Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. 
  • Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. 
  • Preleukemic syndromes and other syndromes predisposing to leukemia. 
  • Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. 
  • Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. 
  • Pseudo-Pelger-Huët anomaly induced by medications: a clinicopathologic study in comparison with myelodysplastic syndrome-related pseudo-Pelger-Huët anomaly. 
  • Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. 
  • Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. 
  • Recent progress in the treatment of myelodysplastic syndrome in adult patients. 
  • Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia. 
  • Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. 
  • Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. 
  • Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. 
  • Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia. 
  • Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). 
  • Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. 
  • Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. 
  • Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. 
  • Telomerase activity in normal leukocytes and in hematologic malignancies. 
  • The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. 
  • The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. 
  • Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. 
  • Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. 
  • Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. 
  • Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens. 
  • Treatment of cutaneous granulocytic sarcoma in a patient with myelodysplasia. 
  • Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). 
  • Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). 
  • Two new polymorphisms but no mutations of the KIT gene in patients with myelodysplasia at positions corresponding to human FMS and murine W locus mutational hot spots. 
  • Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. 
  • Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience. 
  • Use of external ventriculostomy and intrathecal anti-fungal treatment in cerebral mucormycotic abscess. 
  • Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). 
  • What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? 
  • Xist RNA is a potent suppressor of hematologic cancer in mice. 
• 

  Keywords of People

  • Buckley, Rebecca Hatcher, James Buren Sidbury Professor of Pediatrics, in the School of Medicine, Immunology
  • Erba, Harry Paul, Instructor in the Department of Medicine, Duke Cancer Institute
  • Lagoo, Anand Shreeram, Professor of Pathology, Pathology
  • LeBlanc, Thomas William, Associate Professor of Medicine, Duke Cancer Institute
  • Troy, Jesse David, Assistant Professor of Pediatrics, Pediatrics, Blood and Marrow Transplantation
  • Yang, Yiping, Professor of Medicine, Immunology